DoW Toxic Exposures Clinical Trial Award

The DoW Toxic Exposures Clinical Trial Award is a forecasted federal funding opportunity released through the Department of Defense under the Department of the Army, U.S. Army Medical Research Acquisition Activity (USAMRAA). The opportunity is part of the fiscal year 2026 Toxic Exposures Research Program (TERP), which supports medical research related to toxic exposures associated with military service. The program is designed to advance clinical research that can improve the prevention, treatment, or management of symptoms, diseases, and conditions resulting from military-related toxic exposures. The award mechanism specifically supports clinical trial activities and is intended to move promising interventions and knowledge products toward practical clinical application for affected populations. The funding opportunity supports a broad range of clinical trial stages, including small proof-of-concept studies, pilot trials, first-in-human investigations, phase 0 trials, and large-scale efficacy or pragmatic clinical trials. Proposed projects must demonstrate potential for significant impact in addressing toxic exposure-related health conditions affecting military personnel, veterans, or other relevant populations. The program description indicates that projects may range from early feasibility investigations to advanced clinical trials involving relevant patient populations. The mechanism is intended to support rigorous clinical research capable of producing actionable evidence and accelerating translational outcomes. A distinctive feature of this opportunity is the inclusion of a Partnering Principal Investigator Option (PPIO). Under this structure, one investigator serves as the initiating Principal Investigator while an additional investigator may participate as a Partnering Principal Investigator. If selected for funding, each investigator will receive a separate award. The program emphasizes interdisciplinary collaborations, particularly partnerships between clinicians and research scientists, to strengthen translational potential and improve the movement of research findings into clinical practice. The announcement states that collaborations should significantly advance the proposed work beyond what either investigator could achieve independently. The opportunity is categorized under Science and Technology and other Research and Development and is funded under Assistance Listing 12.420, Military Medical Research and Development. The estimated total program funding available for the award mechanism is $4,500,000, with one anticipated award. The funding instrument is a grant. No cost sharing or matching contribution is required. The opportunity is listed as unrestricted, meaning it is open to a wide range of eligible applicants subject to any future clarifications included in the full solicitation materials. Specific award ceiling and award floor amounts were not provided in the forecast notice. The forecast notice was posted on May 7, 2026, with an estimated full opportunity posting date of July 8, 2026. The estimated application due date is November 19, 2026. The estimated award date and project start date are both September 30, 2027. Because the opportunity is forecasted rather than currently open, applicants should monitor the official TERP program website and Grants.gov for release of the full funding opportunity announcement and application instructions. The opportunity appears to follow an annual Department of Defense medical research funding cycle associated with fiscal year appropriations, suggesting recurring availability through future fiscal year TERP announcements. The forecast announcement references the Congressionally Directed Medical Research Programs press release page for additional information regarding the FY26 TERP program. Applicants are expected to use the electronic Biomedical Research Application Portal (eBRAP) and potentially Grants.gov during the submission process once the full announcement is released. At this stage, detailed submission components, evaluation criteria, required forms, and review procedures have not yet been published. The listed contact for applicant assistance is the eBRAP Help Desk, which can be reached at 301-682-5507. No direct program email address or PDF funding announcement link was included in the provided source material.

Emphasize interdisciplinary collaboration between clinicians and research scientists and demonstrate how the proposed clinical trial will significantly advance prevention treatment or management of military-related toxic exposure conditions.